Form 4: NAMS CSO Sells Shares for Tax, Receives New Equity

NewAmsterdam Pharma's Chief Scientific Officer, Johannes Jacob Pieter Kastelein, sold 6,000 shares to cover tax obligations and received new grants of 25,500 restricted stock units and options for 115,000 shares.

Summary

• Johannes Jacob Pieter Kastelein, Chief Scientific Officer and Director of NewAmsterdam Pharma Co N.V. (NAMS), reported transactions in the company's ordinary shares.
• On January 5, 2026, Kastelein sold 6,000 ordinary shares at a weighted average price of $33.25 per share.
• This sale was a pre-arranged 'sell-to-cover' transaction solely to satisfy tax withholding obligations related to the vesting and settlement of restricted stock units (RSUs), and was not a discretionary transaction.
• Following this sale, Kastelein beneficially owned 73,481 ordinary shares directly.
• On January 7, 2026, Kastelein acquired 25,500 Restricted Stock Units (RSUs) for no consideration.
• These RSUs represent a contingent right to receive one ordinary share each, with 1/3 vesting on each of the first, second, and third anniversaries of the vesting start date, subject to continued service.
• Also on January 7, 2026, Kastelein was granted options to buy 115,000 ordinary shares with an exercise price of $35.45 per share and an expiration date of January 7, 2036.
• 25% of the shares underlying the option will vest on January 2, 2027, with the remaining shares vesting in equal monthly installments over the subsequent three years, subject to continued service.
• After these transactions, Kastelein directly beneficially owned 98,981 ordinary shares and 115,000 derivative securities (options).

Sentiment

Score: 7

Explanation: The filing details routine executive compensation activities, including a tax-related share sale and new equity grants. The new equity grants, with their vesting schedules, suggest continued executive commitment and alignment with long-term company performance, which is generally positive.

Positives

• The Chief Scientific Officer received new grants of 25,500 Restricted Stock Units (RSUs) and options for 115,000 ordinary shares, indicating continued commitment and alignment with shareholder interests.
• The RSU and option grants are subject to multi-year vesting schedules, incentivizing long-term service and performance from a key executive.

Negatives

• The sale of 6,000 ordinary shares by a key executive, even if for tax purposes, reduces their direct equity stake in the company.

Risks

• The vesting of RSUs and stock options is contingent upon the Reporting Person's continued service through each vesting date, posing a risk of forfeiture if employment ceases.
• The value of the stock options is dependent on the future market price of NewAmsterdam Pharma's ordinary shares exceeding the exercise price of $35.45.

Future Outlook

The multi-year vesting schedules for the newly granted RSUs and stock options indicate a long-term commitment from the Chief Scientific Officer to the company's future performance and strategic objectives, aligning executive incentives with shareholder value creation over several years.

Industry Context

This filing reflects standard executive compensation practices within the biotechnology and pharmaceutical industries, where equity-based incentives like RSUs and stock options are commonly used to attract, retain, and motivate key scientific and management personnel. The 'sell-to-cover' transaction for tax obligations is also a routine occurrence for executives receiving equity compensation.

Stakeholder Impact

• Shareholders: The transactions provide transparency into executive equity holdings and compensation, which can influence investor confidence and perceptions of management alignment.
• Employees: The equity grants to a key executive may signal stability and long-term vision within the company's leadership.

Next Steps

• Vesting of 1/3 of the 25,500 RSUs on the first, second, and third anniversaries of the vesting start date, subject to continued service.
• Vesting of 25% of the 115,000 options on January 2, 2027, with the remaining vesting in equal monthly installments over the subsequent three years, subject to continued service.

Key Dates

Recommendation

This Form 4 filing details routine executive compensation activities, including a tax-related share sale and new equity grants with standard vesting schedules. These transactions do not provide new fundamental insights into the company's operational performance, financial health, or strategic direction that would warrant a change in an investment thesis. Therefore, a 'hold' recommendation is appropriate as the filing does not present information that would significantly alter the company's valuation or risk profile.

Keywords

NAMS, NewAmsterdam Pharma, Form 4, Insider Transaction, Executive Compensation, Restricted Stock Units, Stock Options, Chief Scientific Officer, Equity Grant, Sell-to-Cover